Metagelan (Metamizole Sodium Monohydrate)

The active ingredient inhibits cyclo‑oxygenase enzymes throughout the body, lowering prostaglandin synthesis. This reduces inflammation, pain signaling, and fever generation. Additionally, it influences central nervous system pathways that modulate pain perception, providing both peripheral and central analgesic effects.

The dosage of Metagelan is determined by the prescribing clinician based on the severity of pain or fever, patient age, weight, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Metagelan in pregnancy and lactation are limited. It should only be used if the potential therapeutic benefit outweighs any possible risk to the fetus or infant, and only under direct medical supervision.

To place an order, submit an enquiry on the Metagelan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metagelan belongs to the pyrazolone class, offering both analgesic and antipyretic effects similar to NSAIDs but with a distinct mechanism of non‑selective COX inhibition. Compared with opioids, it provides pain relief without the risk of dependence, though it carries a rare risk of agranulocytosis not seen with many NSAIDs.

Metagelan should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, direct sunlight, and extreme temperatures to maintain stability.

Metagelan is taken orally as directed by a healthcare professional. It may be administered with or without food, but patients should follow the prescriber’s guidance regarding timing and any accompanying fluids.

The most serious adverse reactions include agranulocytosis, a severe drop in white blood cells that can lead to infection, and anaphylactic shock. Immediate medical attention is required if symptoms such as fever, sore throat, or signs of allergic reaction appear.

Metagelan is contraindicated in individuals with a known hypersensitivity to Metamizole or other pyrazolones, patients with a history of agranulocytosis, and those with severe hepatic or renal impairment unless specifically advised by a physician.